Nav: Home

Anti-aging cosmetic reduced wrinkles in clinical trial

April 28, 2009

Scientists testing a cosmetic anti-ageing product sold on the high street have shown it can clinically reduce wrinkles and improve the appearance of skin damaged by everyday exposure to sunlight.

Dermatologists at The University of Manchester carried out a clinical trial on 60 volunteers with typical signs of sun-damaged skin and found that the cosmetic, No7 Protect & Perfect Intense Beauty Serum, could improve some of these clinical features.

The study, published online in the British Journal of Dermatology today (Tuesday, April 28), showed that 70% of individuals using the beauty product had significantly fewer wrinkles after 12 months of daily use compared to volunteers using a placebo.

The research team, headed by Professor of Dermatology Chris Griffiths, reported last year that the original No7 Protect & Perfect Beauty Serum stimulated the production of fibrillin-1, a protein that promotes elasticity in the skin.

For this latest, year-long study, the researchers first wanted to discover whether the new No7 Protect & Perfect Intense Beauty Serum also promoted fibrillin-1 production but also wished to test whether this would result in a reduction in wrinkles, as has been demonstrated with prescription retinoids.

"Very few over-the-counter cosmetic 'anti-ageing' products have been subjected to a rigorous, scientific trial to prove their effectiveness," said Professor Griffiths, who is based in the University's School of Translational Medicine at Salford Royal Foundation Hospital.

"Although prescription retinoids can have a reparative effect on photo-aged skin, there is scant evidence that any of the plethora of cosmetic 'anti-ageing' products can produce similar effects."

The clinical trial - funded by Boots, the makers of the No7 product range - was carried out using standard scientific protocols. Having established that the No7 Protect & Perfect Intense Beauty Serum did increase fibrillin-1 production, 60 volunteers - 11 men and 49 women aged 45 to 80 years - were recruited to test its efficacy.

The No7 Protect & Perfect Intense Beauty Serum and a control formulation containing no anti-ageing ingredients were supplied in identical, coded packages, so neither investigators nor volunteers were aware as to the treatment of each individual. Thirty volunteers were assigned the No7 Protect & Perfect Intense Beauty Serum and 30 used the placebo formulation.

"Our findings demonstrate that a commercially-available cosmetic can produce significant improvement in the appearance of facial wrinkles following long-term use," said Professor Griffiths.

"It is rare for such benefits to be reported for an over-the-counter anti-ageing product and this study paves the way for larger studies with more statistical power."
-end-
Notes for editors:

A copy of the British Journal of Dermatology paper will be freely available from Tuesday afternoon at: http://www3.interscience.wiley.com/journal/119881892/issue

For an advanced copy of the paper, please contact The University of Manchester press office.

Broadcast-quality footage of Professor Griffiths discussing the findings can be downloaded from: http://manchesteruniversityskincareresearch.co.uk/profcg

If you have problems downloading the footage or would like an edited version please contact The University of Manchester press office.

The Science Media Centre hosted a briefing for national media at its offices in London on Tuesday morning, where Professor Griffiths and Boots Skincare Scientific Adviser Stewart Long reported the findings.

Professor Chris Griffiths is a world-renowned dermatologist and is Associate Dean for Research for The University of Manchester's Faculty of Medical and Human Sciences. His main research foci are on skin ageing and its treatment, the immunological mechanisms of the distressing skin condition psoriasis and the interactions between the brain and the skin. More details about Professor Griffiths can be found at: http://www.medicine.manchester.ac.uk/staff/ChrisGriffiths

The results of the Boots-funded study would have been published in a peer-reviewed scientific journal regardless of outcome. Journalists wishing to speak to Professor Griffiths should contact The University of Manchester press office in the first instance.

University of Manchester

Related Clinical Trial Articles:

First entirely digital clinical trial encourages physical activity
As little as a daily ping on your phone can boost physical activity, researchers from the Stanford University School of Medicine and their collaborators report in a new study.
HIV vaccine nears clinical trial following new findings
A promising vaccine that clears an HIV-like virus from monkeys is closer to human testing after a new, weakened version of the vaccine has been shown to provide similar protection as its original version.
Sickle cell drug showing promise in clinical trial
An investigational drug for the treatment of sickle cell disease is showing early promise in clinical trials for impacting biomarkers of the disease in patients, reported UConn School of Medicine researchers.
Meditation goes digital in new clinical trial
Scientists at UC San Francisco have developed a personalized digital meditation training program that significantly improved attention and memory in healthy young adults -- a group already at the peak of brain health -- in just six weeks.
Could blockchain ensure integrity of clinical trial data?
UC San Francisco researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data with blockchain.
Eating crickets can be good for your gut, according to new clinical trial
A new clinical trial shows that consuming crickets can help support the growth of beneficial gut bacteria and that eating crickets is not only safe at high doses but may also reduce inflammation in the body.
Idera Pharmaceuticals presents clinical data from the ILLUMINATE-204 trial of the combination of tilsotolimod and ipilimumab for anti-PD-1 refractory metastatic melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Idera Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with rare cancers and rare diseases, announced results from the ongoing ILLUMINATE-204 trial investigating tilsotolimod, Idera's intratumorally-delivered Toll-like Receptor 9 agonist, in combination with ipilimumab (Yervoy®).
Clinical trial eligibility criteria a growing obstacle
Despite a decade-long call for simplification of clinical trials, the number of criteria excluding patients from participating in clinical trials for lung cancer research continues to rise.
Clinical trial looks at tramadol for opioid withdrawal
A randomized clinical trial published by JAMA Psychiatry compared tramadol extended-release with clonidine and buprenorphine for the management of opioid withdrawal symptoms in patients with opioid use disorder in a residential research setting.
Vitamin D may improve sunburn, according to new clinical trial
High doses of vitamin D taken one hour after sunburn significantly reduce skin redness, swelling, and inflammation, according to double-blinded, placebo-controlled clinical trial out of Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center.
More Clinical Trial News and Clinical Trial Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Risk
Why do we revere risk-takers, even when their actions terrify us? Why are some better at taking risks than others? This hour, TED speakers explore the alluring, dangerous, and calculated sides of risk. Guests include professional rock climber Alex Honnold, economist Mariana Mazzucato, psychology researcher Kashfia Rahman, structural engineer and bridge designer Ian Firth, and risk intelligence expert Dylan Evans.
Now Playing: Science for the People

#540 Specialize? Or Generalize?
Ever been called a "jack of all trades, master of none"? The world loves to elevate specialists, people who drill deep into a single topic. Those people are great. But there's a place for generalists too, argues David Epstein. Jacks of all trades are often more successful than specialists. And he's got science to back it up. We talk with Epstein about his latest book, "Range: Why Generalists Triumph in a Specialized World".
Now Playing: Radiolab

Dolly Parton's America: Neon Moss
Today on Radiolab, we're bringing you the fourth episode of Jad's special series, Dolly Parton's America. In this episode, Jad goes back up the mountain to visit Dolly's actual Tennessee mountain home, where she tells stories about her first trips out of the holler. Back on the mountaintop, standing under the rain by the Little Pigeon River, the trip triggers memories of Jad's first visit to his father's childhood home, and opens the gateway to dizzying stories of music and migration. Support Radiolab today at Radiolab.org/donate.